93,572 Shares in Avanos Medical, Inc. $AVNS Bought by Squarepoint Ops LLC

Squarepoint Ops LLC purchased a new stake in Avanos Medical, Inc. (NYSE:AVNS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 93,572 shares of the company’s stock, valued at approximately $1,145,000. Squarepoint Ops LLC owned 0.20% of Avanos Medical at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after buying an additional 2,307 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after acquiring an additional 5,083 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Avanos Medical during the 2nd quarter valued at about $126,000. State of Wyoming boosted its stake in Avanos Medical by 104.6% during the 1st quarter. State of Wyoming now owns 10,508 shares of the company’s stock valued at $151,000 after purchasing an additional 5,371 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in shares of Avanos Medical in the first quarter valued at approximately $181,000. Institutional investors and hedge funds own 95.17% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Zacks Research downgraded Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Monday, December 1st. Wall Street Zen upgraded shares of Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Avanos Medical Stock Down 1.8%

AVNS opened at $11.70 on Friday. Avanos Medical, Inc. has a twelve month low of $9.30 and a twelve month high of $17.69. The company’s 50-day moving average price is $11.48 and its two-hundred day moving average price is $11.69. The stock has a market cap of $543.11 million, a price-to-earnings ratio of -1.15 and a beta of 1.09. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.10. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The company had revenue of $177.80 million during the quarter, compared to analyst estimates of $164.50 million. During the same quarter last year, the business posted $0.33 EPS. Avanos Medical’s quarterly revenue was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, equities analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Insider Activity at Avanos Medical

In related news, SVP Kerr Holbrook sold 15,000 shares of Avanos Medical stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the sale, the senior vice president owned 83,860 shares of the company’s stock, valued at approximately $922,460. This trade represents a 15.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.64% of the stock is owned by corporate insiders.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.